Full-Time

Legal Counsel

Posted on 5/9/2026

argenx

argenx

1,001-5,000 employees

Biotech immunology company developing therapeutic antibodies

No salary listed

Remote in Germany

Remote

Category
Legal & Compliance (1)
Requirements
  • German law degree and license to practice law
  • Minimum 5 years of relevant experience in a law firm and/or in biotech/pharma, ideally experience serving as the legal business partner at an international level
  • Fluent in German and English; other language skills preferred
  • Travel required
Responsibilities
  • Represent Legal as a strong business partner that helps build a strong and sustainable business and enables risk-appropriate decision-making
  • Provide strategic, tactical and operational legal and business insight on the commercial launch of argenx product candidates
  • Advise on programs, initiatives, engagements, and materials, related to sales, marketing, market access, non-promotional education activities, patient engagement and scientific exchange
  • Identify training needs within the organization and develop and present training sessions on relevant laws and legal/business issues
  • Stay abreast of and communicate to the organization all significant pending and actual decisions, legislation or related developments that may affect the company
  • Provide advice and legal support on application and maintenance of all authorizations, permits, licenses and communication needed for local operations, including distribution and marketing of products
  • Assess, supervise and manage external legal counsel as appropriate and in line with available budgets
  • Closely coordinate with argenx Compliance colleagues
  • Other duties as assigned
Desired Qualifications
  • Broad based knowledge of general commercial law and regulatory law impacting the pharmaceutical industry
  • First-rate judgment and business acumen, including understanding of business strategy and operations
  • Experience in specialty markets, particularly rare diseases, preferred
  • Ability to work collaboratively and effectively together within cross-functional teams and networks
  • Demonstrated communication skills within a multi-cultural and multi-lingual global environment
  • Is agile and demonstrates adaptability, comfort with ambiguity, trust-building, and resilience
  • Demonstrable experience with project management, proactive planning, priority setting, and securing alignment
  • Drives toward outcomes
  • Ambitious, inquisitive naturally, a quick study, with demonstrated eagerness to continuously learn, self-improve and develop
  • Passionate and prepared to lead and contribute to our culture, which is driven by our corporate values of co-creation, innovation, empowerment, excellence, and humility

argenx develops antibody therapies to treat autoimmune diseases and cancer by translating scientific discoveries in immunology into therapeutic antibodies. Its work centers on R&D and then licensing and collaborations for commercialization, with cusatuzumab being developed with Janssen R&D to target hematological cancers such as leukemia. The company funds and accelerates discovery mainly through partnerships and licenses, bringing products to market via partner-based commercialization rather than building its own sales force. Its goal is to advance antibody-based treatments for serious autoimmune diseases and cancer by turning scientific insights into clinically useful therapies through industry and academic collaborations.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Amsterdam, Netherlands

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • VYVGART drove Q1 2026 revenue to $1.313B, up 63% year-over-year.
  • BofA sets $1,013 target citing Phase 3 myositis readout in Q3 2026.
  • Oppenheimer targets $1,060 after Vyvgart Q4 2025 surge to $1.29B.

What critics are saying

  • FDA rejected VYVGART sBLA for seronegative gMG on May 10, 2026.
  • J&J nipocalimab launches Q4 2026, stealing 20-30% gMG share.
  • Phase 3 myositis trial fails primary endpoint in Q3 2026.

What makes argenx unique

  • Argenx engineers first-in-class antibodies via Immunology Innovation Program.
  • VYVGART first biologic efficacious in ocular myasthenia gravis per ADAPT-OCULUS.
  • Scaled to $4B revenue with under 2,000 employees avoiding bureaucracy.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at argenx who can refer or advise you

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Investing.com
Apr 13th, 2026
Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026.

Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026. Published 04/13/2026, 06:16 AM (C) Reuters. Investing.com - Bank of America has reaffirmed Argenx (NASDAQ:ARGX) and Vertex Pharmaceuticals (NASDAQ:VRTX) as its top large-cap biotech picks for 2026, with price targets of $1,013 and $598, respectively. For Argenx, BofA cited strong commercial performance of Vvygart in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, driven by expansion into earlier treatment lines and growing real-world experience. The firm highlighted upcoming phase 3 results for efgartigimod in myositis in the third quarter and empasiprubart in multifocal motor neuropathy in the fourth quarter as potential catalysts. For Vertex, BofA emphasized the strength of the cystic fibrosis franchise in providing cash flow to support pipeline expansion. The firm identified the rare kidney disease franchise as a key long-term growth driver, noting positive data for povetacicept in IgA nephropathy. Among commercial small- and mid-cap picks, BofA selected KalVista Pharmaceuticals (NASDAQ:KALV) with a $32 price target and Rhythm Pharmaceuticals (NASDAQ:RYTM) with a $149 price target. KalVista's Ekterly was approved in July 2025 as the first on-demand hereditary angioedema therapy, while Rhythm's Imcivree became the first approved therapy for acquired hypothalamic obesity in March. For pre-commercial small- and mid-cap stocks, BofA named Ocular Therapeutix (NASDAQ:OCUL) with a $27 price target and Bicara Therapeutics (NASDAQ:BCAX) with a $35 price target as top picks. Should you invest $2,000 in VRTX right now? ProPicks AI evaluates VRTX alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias - it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if VRTX is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

GlobeNewswire
Apr 7th, 2026
Folia Health launches app-based study to unlock novel real-world evidence of symptom burden and unmet need for patients and caregivers in CIDP.

Folia Health launches app-based study to unlock novel real-world evidence of symptom burden and unmet need for patients and caregivers in CIDP. April 07, 2026 10:00 ET | Source: Folia Health BOSTON, April 07, 2026 (GLOBE NEWSWIRE) - Folia Health today announced a collaboration with argenx to launch a first-of-its-kind, at-home observational real-world evidence initiative supporting individuals living with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). "Our team at Folia shows up to work every day to translate the lived experience of patients into research-grade data that can be used to inform the therapies..." The study represents the first real-world data program designed to capture the at-home experiences of individuals with CIDP and their caregivers. Designed in partnership with patients and caregivers, the initiative leverages Folia's home-reported outcomes (HROs) platform, enabling participants to select and track the symptoms that matter most to them while documenting their individualized treatment plans. Over time, the platform captures symptom severity, treatment utilization, and other aspects of daily disease management directly from patients over an initial six-month period. "Our team at Folia shows up to work every day to translate the lived experience of patients into research-grade data that can be used to inform the therapies available to help people. With our partners at argenx, we are very motivated to be able to describe the diverse experiences of people living with CIDP, including difficulties with nerve pain and symptom flare ups. We hope that this work will pave the way for care plans that enable people with CIDP and their caregivers to achieve a better quality of life with less interference from their disease." said Nell Meosky Luo, the CEO & Founder of Folia Health. HROs tracked by patients and caregivers provide a continuous view of what happens between clinic visits, overlaying tracked symptoms and treatments with real-world quality-of-life impacts such as the ability to work, engage in everyday activities, and navigate life independently. Through the Folia platform, CIDP patients and caregivers can actively engage with their own study data and gain deeper insights into their symptom burden, treatment effects, and acute health events. The Folia app generates tracking summary reports that let patients easily visualize changes over time, including symptom severity trends, flare frequency, and treatment responses. Calendar filtering tools further enable patients to see when symptoms, flares, and other health events occur, which may help them identify patterns and understand how treatments may influence daily life. The platform can overlay treatment usage with symptom severity, and patients can export visual reports to share meaningful insights with their care teams. About Folia Health: Folia Health is a patient-led health company and the pioneer of home-reported outcomes (HROs), transforming lived health experiences into valuable structured data insights to advance research and personalized care. The company's platform is built on the belief that the knowledge of patients and caregivers is the missing piece to enable precise, individualized care and high-impact research. Through a useful platform, radical transparency, explicit consent protocols, and data dividend payments, Folia bridges the gap between patients, clinicians, and researchers while maintaining the highest standards of data privacy and patient autonomy. Founded in 2016 by family caregivers and based in Boston, Folia works with individuals across chronic and rare conditions to generate clinical-grade real-world evidence. For more information, visit www.foliahealth.com. Folia Health Contact: Matt Berry Director of Marketing [email protected]

The Associated Press
Mar 20th, 2026
argenx schedules shareholder meeting for 6 May, proposes board changes

argenx, a global immunology company, will hold its Annual General Meeting on 6 May 2026 at 13:00 CET at the Hilton Amsterdam Schiphol in the Netherlands. The agenda includes routine items such as adopting 2025 annual accounts and an advisory vote on the remuneration report. Several board changes are proposed, including appointing Karen Massey as executive director and Tim Van Hauwermeiren as non-executive director, both for four-year terms. Ana Céspedes, Camilla Sylvest and Pamela Klein are up for re-appointment. Jim Daly will retire as non-executive director and Chair of the Commercialisation Committee, effective 6 May 2026, after serving since May 2018. The board is examining succession options for his role.

Yahoo Finance
Mar 17th, 2026
Argenx shares boosted to $1,060 as Vyvgart revenues surge 74% to $1.29B

Argenx SE has received positive analyst coverage following strong Q4 results. Oppenheimer raised its price target to $1,060 from $1,040 on 26 February, maintaining an Outperform rating, whilst BofA Securities increased its target to $1,013 from $1,006, keeping a Buy rating. The Netherlands-based biotechnology company reported earnings per share of $8.02, surpassing expectations of $5.95, with revenue of $1.29 billion slightly exceeding the $1.28 billion forecast. Vyvgart revenues totalled $1.29 billion in Q4 2025, marking a 74% year-on-year increase. According to Oppenheimer, Vyvgart's myositis readout in Q3 could unlock an additional 20,000-patient opportunity. BofA Securities ranked Argenx as a top pick whilst maintaining flat Vyvgart sales projections for Q1 2026.

GlobeNewswire
Mar 16th, 2026
Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics

Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics...